Initial statement of beneficial ownership of securities – 2/22/2022

Post navigation

← Previous Filings

Next Filings →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-901 for Alzheimer’s Disease
INM-088 for Glaucoma
INM-089 for Age-related Macular Degeneration
Novel Cannabinoid Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA